Skip to main content

"Daddy, I didn't know you're a bad man" - Open Access



I got a call from a tearful girl recently, saying

"Daddy, I didn't know you did bad things at work"

once over the initial shock, I thought what could she be talking about - did she know about the short-cut I use to get to the river to watch the trout?, or that I sometimes asked people in front of me in the queue for the coffee machine to get me a coffee to save my time at the inconsiderate expense of those in front of me? No, it was because I was involved in "Open Access" - lucky then she didn't know then that I was actually really working on a more extreme version - the more fundamentalist version that is the destroyer of capitalism - Open Data! ;)

I said,

"Princess, it's not that bad; honest; Daddy isn't a bad man",

she laughed at my distressed response, and then said

"you should read the Daily Mail then".

This is what she had read.

The Daily Mail is the most widely read UK newspaper, it also is a well known source of shockers about health threats and benefits from just about household object or food, but the fact is it's read by about 4,400,000 million Britons every day.

Here is the introductory paragraph of the article (used under 'fair use').


Up to £1billion of income and thousands of jobs could be placed at risk as a result of a move by Downing Street to allow Google and other digital search engines ‘open access’ to the nation’s best academic and scientific research.

So a lot of jobs are going to go in the UK and we're going to lose 'income' (what is that tax income? sales revenue?, etc). I don't also quite understand the distinction between academic and scientific - I thought the mandatory open access proposals were connected solely with publicly funded research, and don't, and shouldn't, extend to privately sponsored research - if that is behind the distinction. Downing Street and Google are also semi-structured concepts plucked from the ether to build a web of plausibility for what follows - ultimately feeding xenophobia and protectionism.


Here is some more from the article,


But UK businesses fear that the proposals will destroy Britain’s highly-regarded academic publishing industry that modifies raw research, publishes it in the form of academic magazines, journals and books and exports it to the rest of the world.


Use of the word 'exports' is also contrived, most would agree, but which UK businesses will suffer? . Well, it turns out publishing businesses that make significant profits from the current system, they are becoming concerned may be threatened by this proposed change to UK research publication.


You're all intelligent and well informed, so I don't need to comment any more, but just read it, go on, read it!



One leading publishing group said the move to provide all of Britain’s academic output online for nothing could destroy a £1 billion industry that employs 10,000 people here and in its overseas operations.

Much of the scientific work from the nation’s leading research universities is passed on to the academic publishing industry where it is subjected to so-called ‘peer review’, or examination by experts, before it is published in journals and books that are also available online.

The material is a valuable source of income to UK publishing houses such as Reed Elsevier, one of Britain’s leading publishers with a market value of £6billion, as well as the hugely-respected Oxford University and Cambridge University Presses.

and also


In reality academic publishers and researchers fear that scientific and other academic studies, paid for by the taxpayer, will be made freely available to researchers in China and elsewhere in the Far East.


Most rational people would say good to this, that's the way global science is meant to work. Also who were the researchers that would have agreed with this nonsense? I always thought of Reed-Elsevier as a globally operating Anglo-Dutch company, as opposed to deeply rooted and primarily operating within the United Kingdom, which is the impression most readers would be left with.


This is the funniest bit though...


Publishers are concerned that if an open access policy is adopted then some of the biggest scientific companies, such as GlaxoSmithKline, might move research work from British labs to those overseas where it will able to protect itself from open access.



Not attributed to GSK themselves of course but a sort of 'Munchausen's by proxy' worry on behalf of others. The concept of moving overseas to protect your business from open access is just so funny -especially given GSKs activities in pre-competitive activities, collaboration, and Open Data release. 


There's also stuff linking the proposal to make more research available to people to internet piracy, etc.


Seriously though, the fact that this sort of nonsense is read by a very large number of people, and aimed directly at influencing public opinion is, to me, scary. The implicit threats in the article and linkage to economic stability and national competitiveness is, arguably irresponsible.


What have I learnt from this? - well the debate and argument isn't to be held amongst ourselves, it's with the public, the broad base of funders (via their tax contributions, bequests and charitable donations) of our work. We should make them proud of the way we spend their money, we should be accountable for this, and our output should be available for all of them - not just in our own country, but throughout the world. 


Imagine the pride for a researcher mother or father when they get a random call from their kids, saying 


"Hey, I'm so proud that you work in Open Access, and all my friends think you're way cool"



Comments

Noel O'Boyle said…
Why did they report it like this? Is it the worry that traditional media is being supplanted by internet media? Or just that they were lobbied?
jpo said…
It's difficult to say - my guess is that they didn't decide to do a detailed investigative piece to uncover the truth behind the Open Access debate - I read somewhere that most news, is based on overworked and deadline driven journalists them being sent items and polishing them up - allegedly.
R Stephan said…
I'm more paranoid. I think this is part of the publishing houses' strategy: "if truth doesn't work then lie". And it shows to me the heat is ramped up the next step. Fortunately, not many ears are listening. It's simply too obvious that all productivity comes from the authors nowadays.

Popular posts from this blog

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

LSH-based similarity search in MongoDB is faster than postgres cartridge.

TL;DR: In his excellent blog post , Matt Swain described the implementation of compound similarity searches in MongoDB . Unfortunately, Matt's approach had suboptimal ( polynomial ) time complexity with respect to decreasing similarity thresholds, which renders unsuitable for production environments. In this article, we improve on the method by enhancing it with Locality Sensitive Hashing algorithm, which significantly reduces query time and outperforms RDKit PostgreSQL cartridge . myChEMBL 21 - NoSQL edition    Given that NoSQL technologies applied to computational chemistry and cheminformatics are gaining traction and popularity, we decided to include a taster in future myChEMBL releases. Two especially appealing technologies are Neo4j and MongoDB . The former is a graph database and the latter is a BSON document storage. We would like to provide IPython notebook -based tutorials explaining how to use this software to deal with common cheminformatics p

Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

  Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra

Using ChEMBL activity comments

We’re sometimes asked what the ‘activity_comments’ in the ChEMBL database mean. In this Blog post, we’ll use aspirin as an example to explain some of the more common activity comments. First, let’s review the bioactivity data included in ChEMBL. We extract bioactivity data directly from   seven core medicinal chemistry journals . Some common activity types, such as IC50s, are standardised  to allow broad comparisons across assays; the standardised data can be found in the  standard_value ,  standard_relation  and  standard_units  fields. Original data is retained in the database downloads in the  value ,  relation  and  units  fields. However, we extract all data from a publication including non-numerical bioactivity and ADME data. In these cases, the activity comments may be populated during the ChEMBL extraction-curation process  in order to capture the author's  overall  conclusions . Similarly, for deposited datasets and subsets of other databases (e.g. DrugMatrix, PubChem), th